PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Stock Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.885 EUR | -1.87% |
|
-1.70% | -37.28% |
| Sales 2024 * | 1.05M 1.12M | Sales 2025 * | 1.6M 1.71M | Capitalization | 17.86M 19.07M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 1M 1.07M | EV / Sales 2024 * | 17.4 x |
| Net Debt 2024 * | 450K 481K | Net Debt 2025 * | 10.55M 11.27M | EV / Sales 2025 * | 17.8 x |
| P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-3.09
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 week | +0.17% | ||
| Current month | -1.34% | ||
| 1 month | -0.34% | ||
| 3 months | -28.29% | ||
| 6 months | -33.18% | ||
| Current year | -36.09% |
1 week
2.88
2.95
1 month
2.843.00
3 years
2.6075.80
5 years
2.60114.60
10 years
2.60402.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 2.885 | -1.87% | 257 |
| 24-04-22 | 2.94 | +0.68% | 731 |
| 24-04-19 | 2.92 | +0.17% | 4,229 |
| 24-04-18 | 2.915 | -1.19% | 1,337 |
| 24-04-17 | 2.95 | +0.34% | 2,729 |
Real-time Euronext Paris, April 23, 2024 at 04:30 am EDT
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.94
EUR
Average target price
6.85
EUR
Spread / Average Target
+132.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.49% | 96.73B | |
| -0.26% | 21.31B | |
| -16.61% | 21.21B | |
| -5.43% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
